Sign In
Buy MITO
$0.320
+0 (+0%)
At Close: Feb 14, 2023
If You Had Bought Stealth BioTherapeutics (NASDAQ:MITO) Stock A Year Ago, You’d Be Sitting On A 91% Loss, Today
07:21pm, Tuesday, 07'th Apr 2020
As every investor would know, you don't hit a homerun every time you swing. But it should be a priority to avoid...
Investors Who Bought Stealth BioTherapeutics (NASDAQ:MITO) Shares A Year Ago Are Now Down 91%
05:26pm, Tuesday, 07'th Apr 2020
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
Nomura Lowers Stealth BioTherapeutics (NASDAQ:MITO) Price Target to $10.00
09:40am, Tuesday, 07'th Apr 2020
Stealth BioTherapeutics (NASDAQ:MITO) had its price target cut by Nomura from $14.00 to $10.00 in a research report report published on Friday, The Fly reports. They currently have a buy rating on the
Jefferies Financial Group Weighs in on Stealth BioTherapeutics Corp's Q3 2020 Earnings (NASDAQ:MITO)
06:00am, Monday, 06'th Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) – Research analysts at Jefferies Financial Group issued their Q3 2020 EPS estimates for Stealth BioTherapeutics in a research note issued to investors on T
Stealth BioTherapeutics Corp Expected to Post Q1 2020 Earnings of ($0.03) Per Share (NASDAQ:MITO)
05:54am, Saturday, 04'th Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) – Stock analysts at Jefferies Financial Group issued their Q1 2020 EPS estimates for shares of Stealth BioTherapeutics in a report issued on Thursday, Apri
Stealth BioTherapeutics (NASDAQ:MITO) Raised to "Buy" at Zacks Investment Research
08:58am, Friday, 03'rd Apr 2020
Stealth BioTherapeutics (NASDAQ:MITO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports. The brokerage pre
Stealth BioTherapeutics (NASDAQ:MITO) Stock Price Up 7.3% Following Analyst Upgrade
06:16am, Friday, 03'rd Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO)’s share price was up 7.3% during trading on Thursday after BMO Capital Markets raised their price target on the stock from $3.00 to $7.00. BMO Capital Mark
Analyst Explains Why They Upgraded Their Rating on Stealth Biotherapeutics (MITO)
05:33pm, Thursday, 02'nd Apr 2020
In a report released today, Yi Chen from H.C. Wainwright upgraded Stealth Biotherapeutics (MITO) to Buy, with a price target of $5.00. The company's
Analyst Explains Why They Upgraded Their Rating on Stealth Biotherapeutics (MITO)
05:33pm, Thursday, 02'nd Apr 2020
In a report released today,
Yi Chen
from H.C. Wainwright upgraded Stealth Biotherapeutics (
MITO
–
Research Report
) to
Buy
, with a price target of
$5.00
. The company’s shares closed last Thursd
Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action
11:20am, Thursday, 02'nd Apr 2020
Exact Sciences (NASDAQ:EXAS) initiated with an Outperform rating and a $70 (25% upside) price target at Evercore ISI.Health Catalyst (NASDAQ:HCAT) initiated with a Buy rating and a $40 (47% upside) pr
Stealth BioTherapeutics Corp (MITO) Q4 2019 Earnings Call Transcript
06:00pm, Wednesday, 01'st Apr 2020
MITO earnings call for the period ending December 31, 2019.
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q4 2019 Results - Earnings Call Transcript
05:17pm, Wednesday, 01'st Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) Q4 2019 Earnings Conference Call April 01, 2020 08:30 AM ET Company Participants Henry Hess - Chief Legal Counsel Ree
Stealth BioTherapeutics Reports Fiscal Year 2019 Financial Results And Recent Business Highlights
11:30am, Wednesday, 01'st Apr 2020
Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
Stealth BioTherapeutics Corp. to Host Earnings Call
10:30am, Wednesday, 01'st Apr 2020
NEW YORK, NY / ACCESSWIRE / April 1, 2020 / Stealth BioTherapeutics Corp. (NASDAQ:MITO) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on April 1, 2020
Stealth BioTherapeutics to Report Full Year 2019 Financial Results on Wednesday, April 1, 2020
12:30pm, Monday, 30'th Mar 2020
Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
